HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 335 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,309,421 | +5.7% | 426,940 | -0.2% | 0.01% | +10.0% |
| Q2 2023 | $15,436,914 | -5.6% | 427,971 | -0.0% | 0.01% | -9.1% |
| Q1 2023 | $16,346,825 | -55.4% | 428,064 | -33.5% | 0.01% | -57.7% |
| Q4 2022 | $36,651,336 | +34.3% | 644,142 | -53.3% | 0.03% | +30.0% |
| Q3 2022 | $27,292,265 | -9.8% | 1,379,072 | +100.4% | 0.02% | -4.8% |
| Q2 2022 | $30,274,000 | +4.0% | 688,040 | -5.7% | 0.02% | +50.0% |
| Q1 2022 | $29,103,000 | +7.8% | 729,775 | +8.7% | 0.01% | +27.3% |
| Q4 2021 | $27,004,000 | +0.8% | 671,571 | +2.0% | 0.01% | -8.3% |
| Q3 2021 | $26,784,000 | -9.5% | 658,395 | +1.0% | 0.01% | -7.7% |
| Q2 2021 | $29,601,000 | +3.9% | 651,856 | -4.6% | 0.01% | 0.0% |
| Q1 2021 | $28,481,000 | -16.6% | 683,169 | -14.5% | 0.01% | -18.8% |
| Q4 2020 | $34,143,000 | +46.1% | 799,410 | -10.1% | 0.02% | +33.3% |
| Q3 2020 | $23,371,000 | – | 889,303 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |